Sacituzumab govitecan is a Monoclonal Antibody Conjugated owned by Gilead Sciences, and is involved in 55 clinical trials, of which 3 were completed, 35 are ongoing, and 17 are planned. Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. Sacituzumab govitecan-hziy composed of the three components: 1. humanized monoclonal antibody, hRS7 IgG1κ (also called sacituzumab), which binds to Trop-2 (the trophoblast cell-surface antigen-2); 2. the drug SN-38, a topoisomerase inhibitor & 3. a hydrolysable linker (called CL2A), which links the humanized monoclonal antibody to SN-38. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death.

The revenue for Sacituzumab govitecan is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sacituzumab govitecan NPV Report.

Sacituzumab govitecan was originated by Immunomedics and is currently owned by Gilead Sciences. Everest Medicines is the other company associated in development or marketing of Sacituzumab govitecan.

Sacituzumab govitecan Overview

Sacituzumab govitecan (Trodelvy) is a conjugated humanized monoclonal antibody with potential antineoplastic activity. It is formulated as lyophilized powder for solution for intravenous route of administration. Trodelvy is indicated for the treatment of adult patients with unresectable or locally advanced metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Sacituzumab govitecan (IMMU-132) is under development for the treatment of advanced or metastatic urothelial carcinoma, papillary thyroid cancer, hepatocellular carcinoma, refractory or relapsed advanced including epithelial ovarian cancer, colorectal, gastric, hepatocellular, bladder cancer, head and neck squamous cell carcinoma, metastatic hormone-refractory prostate, small-cell and metastatic non-small-cell lung cancer, pancreatic ductal adenocarcinoma, HER2 negative breast cancer, esophageal, renal cell cancer, metastatic transitional (Urothelial) tract cancer, endometrial cancer, cervical cancer, esophageal squamous cell carcinoma (escc), glioblastoma multiforme malignant glioma, muscle invasive bladder cancer and metastatic breast cancer with brain metastasis. It is administered as an intravenous route. IMMU-132 is a camptothecin-based ADC where the antibody, RS7 is attached to SN38. IMMU-132 targets cells expressing TROP-2. It was also under development for follicular thyroid cancer and adenocarcinoma.

Everest Medicines Overview

Everest Medicines, is a biopharmaceutical company that licenses, develops and commercializes medicines for the treatment of cancer, autoimmune, cardio renal and infectious diseases. It is investigating Sacituzumab govitecan, an antibody-drug conjugate targeting metastatic triple-negative breast cancer (mTNBC), metastatic urothelial cancer (mUc), non-small cell lung cancer (NSCLC) and other oncology indications; and FGF401 for hepatocellular carcinoma. The company is evaluating Etrasimod to treat ulcerative colitis and other autoimmune diseases; Nefecon for IgA nephropathy; Ralinepag against pulmonary arterial hypertension (PAH). Everest Medicines is also developing drugs for community-acquired bacterial pneumonia (CABP), complicated urinary tract infection (cUTi) and other infectious diseases. It works in partnership with Immunomedics, Novartis, Arena Pharmaceuticals and other companies to develop its products. Everest Medicines is headquartered in Shanghai, China.

The company reported revenues of (Renminbi) CNY0.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was CNY1,026.3 million in FY2021, compared to an operating loss of CNY688.5 million in FY2020. The net loss of the company was CNY1,008.7 million in FY2021, compared to a net loss of CNY5,658.2 million in FY2020.

Quick View – Sacituzumab govitecan

Report Segments
  • Innovator (NME)
Drug Name
  • Sacituzumab govitecan
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.